• Contemporary ClinicContemporary Clinic
  • OTC GuideOTC Guide
  • Pharmacy Times
  • PTCEPTCE
  • Pharmacist Moms GroupPharmacist Moms Group
News
All News
FDA Updates
Press Releases
Media
All Videos
Digital Detail
Independent Corner
Insights
Interviews
MEDcast
Medical World News
Microsites
Peer Exchange
Perfect Consult
Podcasts
Practice Pearls
Sponsored Webcast
Student Voices
Webinars/Webcasts
Conferences
Conference Coverage
Conference Listing
Publications
Pharmacy Times
Pharmacy Practice in Focus: Oncology
Pharmacy Practice in Focus: Health Systems
Pharmacy Careers
All Publications
About the Publications
Author Submission
Submit to Pharmacy Practice in Focus: Oncology
Submit to Pharmacy Practice in Focus: Health Systems
Become a Peer Reviewer
Supplements & Featured Publications
Clinical
503B Compounding Pharmacy
ADHD
Allergy
Alzheimer Disease
Anxiety
Asthma
Atopic Dermatitis
Biosimilars
Bipolar Disorder
Brain Health
Breast Cancer
C. Difficile
COPD
COVID-19
Cardiovascular Health
Cervical Cancer
Cholangiocarcinoma
Cholesterol
Chronic Kidney Disease
Chronic Lymphocytic Leukemia
Classical Hematology
Colorectal Cancer
Continuous Glucose Monitoring
Cough and Cold
Depression
Dermatology
Diabetes
Digestive Health
Dry Eye Disease
Epilepsy
Eye Care
Flu
Future of Pharmacy
Gastrointestinal Cancer
Gastrointestinal Health
Gout
HER2 Breast Cancer
HIV
Heart Failure
Hematology
Hepatitis/MASH
Immunization
Immuno-oncology
Immunoglobulins
Infectious Disease
Lung Cancer
Lymphoma
Macular Degeneration
Mental Health
Migraine
Multiple Myeloma
Multiple Sclerosis
Myelofibrosis
Neurology
Neutropenia
Osteoporosis
Ovarian Cancer
Pain Management
Parkinson Disease
Pediatrics
Pharmacy Heroes
Pharmacy Management
Pneumococcal
PrEP
Prostate Cancer
Psoriasis
Psoriatic Arthritis
Psychedelics
Reimbursement
Reproductive Health
Respiratory Syncytial Virus
Rheumatoid Arthritis
Schizophrenia
Shingles
Skin Cancer
Sleep
Travel Vaccines
Veterinary Pharmacy
Vitamins and Supplements
Weight Management
Women's Health
Events
Upcoming Events
Upcoming Webinars
CE
Resources
Clinical Forum
Cou-Co
Educated Patient
Information for the Pharmacist
Interactive Tools
Partners
Sponsored
Whiteboards
Subscribe
logo
Spotlight
Community/RetailHospitalOncologyPharmacy TechnicianStudent
Clinical Role
Community/RetailHospitalOncologyPharmacy TechnicianSpecialty PharmacyStudent
Clinical
CoronavirusBrain HealthCardiovascular HealthDermatologyDiabetesFluHeart FailureHepatitis/MASHImmunizationMigrainePneumococcalVitamins and Supplements
Supplement Spotlight
October 2023 Pharmacy Technician Edition
All News
FDA Updates
Press Releases
All Videos
Digital Detail
Independent Corner
Insights
Interviews
MEDcast
Medical World News
Microsites
Peer Exchange
Perfect Consult
Podcasts
Practice Pearls
Sponsored Webcast
Student Voices
Webinars/Webcasts
Conference Coverage
Conference Listing
Pharmacy Times
Pharmacy Practice in Focus: Oncology
Pharmacy Practice in Focus: Health Systems
Pharmacy Careers
All Publications
About the Publications
Author Submission
Submit to Pharmacy Practice in Focus: Oncology
Submit to Pharmacy Practice in Focus: Health Systems
Become a Peer Reviewer
Supplements & Featured Publications
503B Compounding Pharmacy
ADHD
Allergy
Alzheimer Disease
Anxiety
Asthma
Atopic Dermatitis
Biosimilars
Bipolar Disorder
Brain Health
Breast Cancer
C. Difficile
COPD
COVID-19
Cardiovascular Health
Cervical Cancer
Cholangiocarcinoma
Cholesterol
Chronic Kidney Disease
Chronic Lymphocytic Leukemia
Classical Hematology
Colorectal Cancer
Continuous Glucose Monitoring
Cough and Cold
Depression
Dermatology
Diabetes
Digestive Health
Dry Eye Disease
Epilepsy
Eye Care
Flu
Future of Pharmacy
Gastrointestinal Cancer
Gastrointestinal Health
Gout
HER2 Breast Cancer
HIV
Heart Failure
Hematology
Hepatitis/MASH
Immunization
Immuno-oncology
Immunoglobulins
Infectious Disease
Lung Cancer
Lymphoma
Macular Degeneration
Mental Health
Migraine
Multiple Myeloma
Multiple Sclerosis
Myelofibrosis
Neurology
Neutropenia
Osteoporosis
Ovarian Cancer
Pain Management
Parkinson Disease
Pediatrics
Pharmacy Heroes
Pharmacy Management
Pneumococcal
PrEP
Prostate Cancer
Psoriasis
Psoriatic Arthritis
Psychedelics
Reimbursement
Reproductive Health
Respiratory Syncytial Virus
Rheumatoid Arthritis
Schizophrenia
Shingles
Skin Cancer
Sleep
Travel Vaccines
Veterinary Pharmacy
Vitamins and Supplements
Weight Management
Women's Health
Upcoming Events
Upcoming Webinars
CE
Clinical Forum
Cou-Co
Educated Patient
Information for the Pharmacist
Interactive Tools
Partners
Sponsored
Whiteboards
Subscribe
Advertisement

CLINICAL ROLE -

Community/Retail
| Hospital
| Oncology
| Pharmacy Technician
| Student

Article

June 5, 2017

Trending News Today: Patients Struggling to Manage COPD Drug Costs

Author(s):

Lauren Santye, Assistant Editor

Top news of the day from across the health care landscape.

Medicare patients with chronic obstructive pulmonary disease (COPD) struggle to afford treatment, Kaiser Health News reported. COPD was the third leading cause of death in the United States in 2014, according to the CDC. An estimated 1 of 9 Medicare beneficiaries are diagnosed with the disease, and inhalers, such as Spiriva and Advair, account for billions in annual Medicare spending. Unfortunately, prices only continue to climb. The list price of Spiriva increased 31% over the past 5 years to $368 for a 30-day supply, KHN reported. Although drug manufacturers have said that insured patients would not pay the list prices because of rebates, discounts, and other price concessions, many patients will be on more than one inhaler. In a recent letter published in JAMA, investigators evaluated Medicare’s prescription drug formularies in 2015 and the projected cost of copayments and deductibles. The findings show that Medicare Part D beneficiaries who had multiple inhalers could spend more than $2800 in out-of-pocket costs per year.

Findings from a major international study revealed that many patients with colon cancer can cut the length of treatment by half, ultimately improving their quality of life and reducing severe adverse events. According to The Washington Post, investigators sought to determine if a 3-month chemotherapy regimen was as effective as 6 months of treatment in patients with stage 3 colon cancer. The investigators obtained data from 6 clinical trials that included nearly 13,000 patients with colon cancer in North America, Europe, and Asia. The results of the study showed that 74.6% of patients in the 3-month regimen arm were cancer-free at 3 years compared with 77.5% in the 6-month regimen arm. The authors concluded that the 3-month treatment was nearly as effective as the longer treatment, and is likely to become a new standard of care.

Patients with metastatic cancer who regularly used a web-based tool to report symptoms while undergoing chemotherapy lived a median of 5 months longer than those who did not use the tool, a recent study found. The investigators enrolled 766 patients with advanced solid tumors who were receiving outpatient chemotherapy, according to Cancer Network. The participants were randomized to either report their symptoms via tablet computers to a group whose symptoms were monitored and documented by clinicians, as per usual. The results of the study showed that nurses took immediate clinical action more than three-quarters of the time when severe or worsening symptoms were reported using the web tool, compared with patients who received usual care. Patients who used the tool to self-report symptoms had a longer median overall survival of 31.2 months compared with 26 months among patients who received usual care. The findings were presented at the 2017 Annual Society of Clinical Oncology Annual Meeting in Chicago.

Related Videos
Pharmacist and patient in a retail/community pharmacy setting -- Image credit: Zamrznuti tonovi | stock.adobe.com
Menoapuse spelled with wooden blocks -- Image credit: loran4a | stock.adobe.com
Related Content
Advertisement
Olaparib box | Image Credit: © luchschenF - stock.adobe.com
May 15th 2025

Gap-Scheduled Olaparib Plus Neoadjuvant Chemotherapy Improved Survival in Patients With gBRCAm TBNC

Alexandra Gerlach, Associate Editor
pharmacy focus oncology edition
May 12th 2025

Insights from a Pharmacy Times Peer Exchange: Emerging ADCs and Real-World Management

Alexandra Gerlach, Associate Editor
CAR T-cell visualization | Image Credit: © Wimon - stock.adobe.com
May 14th 2025

Anitocabtagene Autoleucel Yields Overall Response Rate of 97% in Patients With Multiple Myeloma

Alexandra Gerlach, Associate Editor
Pharmacy Times pharmacy focus oncology edition
May 5th 2025

Novel HER2-low Therapies and Pharmacist-Led ADC Sequencing

Alexandra Gerlach, Associate Editor
Cancer cells, 3D illustration
May 14th 2025

FDA Approves Belzutifan for Treatment of Locally Advanced, Unresectable, or Metastatic Pheochromocytoma and Paraganglioma

Luke Halpern, Assistant Editor
psoriasis is an autoimmune human disease. a man holds a hand at a psoriasis affected area of the skin
May 14th 2025

Icotrokinra Demonstrates Significant Skin Clearance in Difficult-to-Treat Scalp, Genital Psoriasis

Luke Halpern, Assistant Editor
Related Content
Advertisement
Olaparib box | Image Credit: © luchschenF - stock.adobe.com
May 15th 2025

Gap-Scheduled Olaparib Plus Neoadjuvant Chemotherapy Improved Survival in Patients With gBRCAm TBNC

Alexandra Gerlach, Associate Editor
pharmacy focus oncology edition
May 12th 2025

Insights from a Pharmacy Times Peer Exchange: Emerging ADCs and Real-World Management

Alexandra Gerlach, Associate Editor
CAR T-cell visualization | Image Credit: © Wimon - stock.adobe.com
May 14th 2025

Anitocabtagene Autoleucel Yields Overall Response Rate of 97% in Patients With Multiple Myeloma

Alexandra Gerlach, Associate Editor
Pharmacy Times pharmacy focus oncology edition
May 5th 2025

Novel HER2-low Therapies and Pharmacist-Led ADC Sequencing

Alexandra Gerlach, Associate Editor
Cancer cells, 3D illustration
May 14th 2025

FDA Approves Belzutifan for Treatment of Locally Advanced, Unresectable, or Metastatic Pheochromocytoma and Paraganglioma

Luke Halpern, Assistant Editor
psoriasis is an autoimmune human disease. a man holds a hand at a psoriasis affected area of the skin
May 14th 2025

Icotrokinra Demonstrates Significant Skin Clearance in Difficult-to-Treat Scalp, Genital Psoriasis

Luke Halpern, Assistant Editor
Consent Preferences
About Us
Clinical Forums
Advertise
Contact Us
Editorial Staff
Privacy Policy
Terms & Conditions
Do Not Sell My Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.